Symbiotec signs 10-year European CDMO deal, plans 750 KL

Symbiotec Pharmalab Limited has signed a 10-year take-or-pay manufacturing agreement with a Europe-based alternate-protein company, with management linking Phase 1 to 750 kilolitres (KL) of new fermentation capacity at Ujjain. The programme begins with technology transfer and qualification work at the existing 100 KL scale, management said on November 6, 2026.

What does Symbiotec's European agreement cover?

Symbiotec will provide fermentation development and manufacturing services under a 10-year take-or-pay agreement with a Europe-based alternate-protein company. Management confirmed the signed contract during its Q2 and H1 FY27 earnings call on November 6, 2026, after previously describing the customer discussion as pending.

The first stage is technology transfer and qualification batches at Symbiotec's existing 100 KL fermentation scale in Ujjain. Management said the customer's technology had already been successfully scaled up at that facility and estimated that remaining fine-tuning could take about three months before Phase 0 production starts.

Symbiotec said its role extends beyond supplying fermenter capacity. The company described the service as covering technology improvement, scale-up and commercialisation support, including work intended to achieve viable unit economics for the customer's alternate-protein product.

The European contract is the second alternate-protein agreement disclosed by Symbiotec. Its separate 10-year take-or-pay contract with a US-based alternate-protein company is expected to begin commercial batches in Q1 FY28, after completion of downstream capability for that product.

How will Symbiotec build 750 KL for the European customer?

Symbiotec said the 750 KL figure in its presentation refers to Phase 1 of the European alternate-protein agreement. Management estimated that building this Phase 1 capacity at Ujjain would take 12 to 15 months, following the 100 KL Phase 0 qualification and production stage.

Management's prepared remarks also referred to building 250,000 litres, or 250 KL, after the 100 KL starting scale. The call did not explain whether the 250 KL figure is an initial module within the later-cited 750 KL Phase 1 plan or a separate capacity proposal.

The longer-term project could require substantially more capacity than the Phase 1 plan. Management said Phase 2 would exceed 1 million litres and that the two phases together could require a few million litres over time, while estimating total cost at roughly Rs 1,000 crore by the end of Phase 2.

Symbiotec said the customer would contribute significantly to project costs rather than the company bearing the full capital outlay. The company did not disclose the customer contribution, its own final funding requirement, or a phase-wise capital expenditure schedule for the 750 KL project.

When could Symbiotec's European contract begin contributing revenue?

Symbiotec expects Phase 0 revenue from the European programme to begin towards the end of FY27 and continue through FY28. Management said Phase 0 would not be the principal revenue stage, while Phase 1 would become the major source of toll-fee income after the 12-to-15-month construction period.

Management identified FY28-29 as the period when Phase 1 could enter its more meaningful revenue phase. It did not disclose the contract value, annual production volume, tolling rate or profitability of the European agreement, citing confidentiality.

The revenue ramp also depends on approvals and execution. Management said certain Indian approvals were in progress, while the European customer already had product approvals in Europe and the US; it also said detailed project reports and other preparation had been completed after engagement with the customer over the preceding quarters.

Symbiotec's reported Q2 FY27 financial performance was driven primarily by its established businesses rather than this new contract. Consolidated revenue was Rs 280 crore, up 43% year on year, including Rs 53 crore of recognised complex-injectable milestone revenue, while API revenue was Rs 227 crore, up 16%.

How does the European deal fit Symbiotec's fermentation strategy?

Symbiotec's European contract adds a second alternate-protein anchor to its fermentation contract base, alongside the US programme and a five-year insulin drug-substance agreement. The company said its Ujjain site had 400 KL of fermentation capacity as of November 6, 2026 and was designed for phased expansion as contracts are signed.

The Ujjain site now comprises about 70 to 72 acres after Symbiotec added roughly 40 acres to the 32 acres already in its possession. Management said future fermentation CDMO capacity additions would be developed at this location.

The insulin drug-substance programme has a different commissioning schedule from the European alternate-protein project. Symbiotec expects the biologics facility to be commissioned in Q4 FY27, with validation batches in that quarter and sales commencing around the middle to later part of FY28 after regulatory approvals.

Management said it had invested more than Rs 1,000 crore in new business verticals, including fermentation CDMO and complex injectables. H1 FY27 capital expenditure was Rs 113 crore and net debt stood at Rs 314 crore on September 30, providing financial context for the planned fermentation expansion.

In response to an analyst, management said it targeted return on capital employed of at least 30%, earnings before interest, tax, depreciation and amortisation margins of 30% to 40%, and gross margins of 70% to 80% for biomanufacturing and biopharma work. It said these were broad expectations that could vary by product, customer and geography, not specific guidance for the European agreement.

Conclusion

The signed European agreement moves Symbiotec from a pending alternate-protein customer discussion to a phased manufacturing programme, beginning at 100 KL and progressing to a stated 750 KL Phase 1 plan. Together with the US alternate-protein contract and the insulin drug-substance programme, it broadens the company's fermentation CDMO pipeline beyond the API business, which generated Rs 227 crore of Q2 FY27 revenue.

The next milestones are Phase 0 production by the end of FY27, the proposed 12-to-15-month construction period for the 750 KL Phase 1 facility, and progress on Indian approvals. Management also needs to clarify the relationship between the 250 KL capacity stated in prepared remarks and the 750 KL Phase 1 figure cited later in the call.